This course will provide a comprehensive overview of the regulatory, quality and GMP requirements to consider when developing ATMPs.
This course has been designed to provide a comprehensive overview of the regulatory, quality and good manufacturing practice (GMP) requirements to consider when developing advanced therapy medicinal products (ATMPs).
Industry expterts will cover the regulatory landscape and the definition and classification of ATMPs and provide practical guidance on how to overcome quality and specific GMP challenges. The differences between GMP for ATMPs and conventional therapies will be discussed, as will the requirements for clinical trials and the preparation of the IMPD. Advice on the specific transportation requirements of
these products will also be addressed.
This programme will be of benefit to all those involved with or considering developing an AMTP.
Benefits of attending:
This seminar will be of benefit to all those involved with or considering developing an Advance Medicinal Therapeutic Product.
Andrew Willis
Andrew Willis is an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously, he worked for Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services, where he was head of a team of internal and external regulatory affairs consultants.
He qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He had 10 years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs. He has over 30 years’ pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment.
He has extensive experience of major European and US regulatory projects, in the clinical and marketing authorisation stages, and has significant experience in coordinating and managing meetings with European and US Health Authorities.
| 30-31 Mar 2020 | |||
| 30-31 Mar 2020 | Rembrandt Hotel, London | GBP 1,499.00 EUR 2,099.00 USD 2,338.00 + VAT @ 20.00% |
Enrol now |
| 5-6 Oct 2020 | |||
| 5-6 Oct 2020 | Rembrandt Hotel, London | GBP 1,499.00 EUR 2,099.00 USD 2,338.00 + VAT @ 20.00% |
Enrol now |
“Great and really interesting.”
Heloise Armand, Quality Director, Genzyme Polyclonals
“I think Andrew Willis was very entertaining. and had good answers. Maybe even more examples from real life would be good.”
Ida Kjær, QA Professional, Novo Nordisk A/S
“Very good! ”
Marie-Charlotte Royer, Quality Engineer, Urgo RID
“Great depth of experience. Well presented, very intense and in-depth material. ”
Elizabeth Watson, Scientific Writer, Hookipa Biotech